AxoGen (AXGN) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Axogen, Inc. Reports 2018 Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 4:01 PM ESTFourth Quarter Revenue of $23.4 million, representing 38% growth over prior yearFull Year 2018 Revenue of $83.9 million, representing 39% growth over prior year
ALACHUA, Fla., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.
Fourth Quarter 2018 Financial Results and Recent Business Highlights
Revenue of $23.4 million, up 38% compared to fourth quarter 2017 revenue of $17.0... More